Trial status: Completed

Trial name: Memantine in Huntington's

Sponsor: Forest Pharmaceuticals, Inc.

Results: Preliminary analysis results presented at the HSG Huntington's Disease Symposium in 2010 suggested that 20 mg dosing of memantine resulted in improvement in certain (not all) cognitive measures, but worsening of motor symptoms (which motor symptoms were not described). The final analysis of data and full trial results have not been made public.